CN113603676B - 基于厄洛替尼靶向降解egfr蛋白小分子化合物及其制备方法和应用 - Google Patents
基于厄洛替尼靶向降解egfr蛋白小分子化合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN113603676B CN113603676B CN202110468180.6A CN202110468180A CN113603676B CN 113603676 B CN113603676 B CN 113603676B CN 202110468180 A CN202110468180 A CN 202110468180A CN 113603676 B CN113603676 B CN 113603676B
- Authority
- CN
- China
- Prior art keywords
- compound
- erlotinib
- egfr protein
- formula
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 title claims abstract description 32
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 title claims abstract description 32
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 title claims abstract description 18
- 239000005551 L01XE03 - Erlotinib Substances 0.000 title claims abstract description 17
- 229960001433 erlotinib Drugs 0.000 title claims abstract description 17
- 238000006731 degradation reaction Methods 0.000 title claims abstract description 13
- 230000015556 catabolic process Effects 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title abstract description 22
- -1 small molecule compound Chemical class 0.000 title abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 58
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims abstract description 20
- 230000017854 proteolysis Effects 0.000 claims abstract description 13
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 17
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 11
- 239000012074 organic phase Substances 0.000 claims description 10
- 238000005406 washing Methods 0.000 claims description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- 238000004440 column chromatography Methods 0.000 claims description 9
- 230000034512 ubiquitination Effects 0.000 claims description 9
- 238000010798 ubiquitination Methods 0.000 claims description 9
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 8
- 229930003268 Vitamin C Natural products 0.000 claims description 8
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 claims description 8
- 235000019154 vitamin C Nutrition 0.000 claims description 8
- 239000011718 vitamin C Substances 0.000 claims description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 4
- 239000003480 eluent Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000012295 chemical reaction liquid Substances 0.000 claims description 3
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 230000000259 anti-tumor effect Effects 0.000 abstract description 5
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 abstract description 5
- 229960000688 pomalidomide Drugs 0.000 abstract description 5
- 108010026668 snake venom protein C activator Proteins 0.000 abstract description 5
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 abstract description 4
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- 238000000338 in vitro Methods 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 abstract description 3
- 230000005918 in vitro anti-tumor Effects 0.000 abstract description 2
- 238000011865 proteolysis targeting chimera technique Methods 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 11
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 10
- 238000004809 thin layer chromatography Methods 0.000 description 10
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical group [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 description 4
- 102100025677 Alkaline phosphatase, germ cell type Human genes 0.000 description 4
- 101000574440 Homo sapiens Alkaline phosphatase, germ cell type Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 102000044159 Ubiquitin Human genes 0.000 description 4
- 108090000848 Ubiquitin Proteins 0.000 description 4
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 3
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000012049 topical pharmaceutical composition Substances 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 2
- KAFZOLYKKCWUBI-HPMAGDRPSA-N (2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-3-amino-2-[[(2s)-2-[[(2s)-2-(3-cyclohexylpropanoylamino)-4-methylpentanoyl]amino]-5-methylhexanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CCC(C)C)C(=O)N[C@@H](CN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(N)=O)C(=O)CCC1CCCCC1 KAFZOLYKKCWUBI-HPMAGDRPSA-N 0.000 description 2
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 2
- VGNCBRNRHXEODV-XXVHXNRLSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-6-dodecoxy-4,7-dihydroxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@H](O)[C@H](C(O2)(C(O)=O)C(O)(C(O1)C(O)=O)C(O)=O)OCCCCCCCCCCCC)C1=CC=CC=C1 VGNCBRNRHXEODV-XXVHXNRLSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102000015367 CRBN Human genes 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940121647 egfr inhibitor Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 2
- 230000006663 ubiquitin-proteasome pathway Effects 0.000 description 2
- QKLXBIHSGMPUQS-FGZHOGPDSA-M (3r,5r)-7-[4-(4-fluorophenyl)-2,5-dimethyl-1-phenylpyrrol-3-yl]-3,5-dihydroxyheptanoate Chemical compound CC1=C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C=2C=CC(F)=CC=2)=C(C)N1C1=CC=CC=C1 QKLXBIHSGMPUQS-FGZHOGPDSA-M 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000036364 Cullin Ring E3 Ligases Human genes 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 102000018478 Ubiquitin-Activating Enzymes Human genes 0.000 description 1
- 108010091546 Ubiquitin-Activating Enzymes Proteins 0.000 description 1
- 108010005705 Ubiquitinated Proteins Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000003541 multi-stage reaction Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940124823 proteolysis targeting chimeric molecule Drugs 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了一种基于厄洛替尼靶向降解EGFR蛋白小分子化合物及其制备方法和应用,该化合物(I)或其药学上可接受的盐或水合物,以及包含该化合物的药物组合物可应用于制备预防或/和治疗癌症的药物;本发明选用泊马度胺作为PROTACs中与E3连接酶进行结合的部位,厄洛替尼为靶向EGFR小分子化合物,选用合适的连接链将两者相连接构建PROTACs,体外抗肿瘤活性测试及体外EGFR蛋白降解活性表明,本发明化合物表现出了良好的抗肿瘤活性,并表现出优异的EGFR蛋白降解作用,可用于预防或/和治疗多种癌症,在医药领域具有巨大的应用前景。
Description
技术领域
本发明涉及一种靶向降解EGFR蛋白的化合物及其制备方法和应用。
背景技术
泛素-蛋白酶体系统(ubiquitin proteasome systerm,UPS)是细胞内蛋白质降解的主要途径,参与细胞内80%以上蛋白质的降解,UPS属于一个多步骤反应过程,有多种不同蛋白质参与,蛋白质先被泛素(多肽)标记,然后被蛋白酶体识别和降解。
该系统由泛素、泛素活化酶E1、泛素结合酶E2、泛素连接酶E3、蛋白酶体及其底物(蛋白质)构成。UPS特异性降解蛋白质的过程分两个阶段:(1)蛋白底物泛素化:泛素分子由APP提供能量,被E1激活转移到E2,然后经E3与特异性蛋白底物结合;(2)蛋白底物降解:被泛素化的蛋白分子能够被蛋白酶体识别,并进入蛋白酶体降解成短链的多肽分子。
蛋白水解靶向嵌合分子(Proteolysis Targeting Chimeras,PROTACs)是利用一种双功能小分子将目标蛋白和细胞内的E3拉近,从而导致目标蛋白质的降解。PROTACs包含三部分功能结构:(1)可以与蛋白底物相结合的部分;(2)能够与E3相结合的部分;(3)前两部分的连接链(Linker)。细胞内PROTACs可以同时与靶蛋白及E3结合,使本来不能与E3结合的靶蛋白泛素化,进而被蛋白酶体识别并降解(Angew.Chem.Int.Ed.Engl.,2016,55(6),1996-1973)。
研究证明,泊马度胺可以与CRBN蛋白结合,CRBN蛋白为CUL4-RBX1-DDB1-Cereblon(CRL4CRBN)E3泛素连接酶复合物的底物受体蛋白,结合后通过泛素-蛋白酶体途径进行蛋白水解(Nature,2014,512(7512):49-53)。
当前,在许多实体肿瘤中存在EGFR的高表达或异常表达,EGFR与肿瘤细胞的增殖、血管生成、肿瘤侵袭、转移及细胞凋亡的抑制有关。EGFR的过表达在恶性肿瘤的演变进中起重要作用,胶质细胞、肾癌、肺癌、前列腺癌、胰腺癌、乳腺癌等组织中都有EGFR的过表达。EGFR已成为有效的抗肿瘤靶点,多个EGFR抑制剂已经上市用于多种癌症的治疗。但是目前所用的EGFR抑制剂抑制效果有限,且已存在一定的耐药问题,因此,开发出一种可降解EGFR蛋白的化合物具有极其重要的制药价值。
发明内容
本发明提供了一种基于厄洛替尼靶向泛素化诱导EGFR蛋白降解的化合物及其制备方法和应用,该化合物不仅具有EGFR蛋白降解作用和抗肿瘤活性,且对人体毒副作用小,可用于制备抗肿瘤药物。
本发明的技术方案如下:
一种式(I)所示的靶向泛素化诱导EGFR蛋白降解的化合物或其药学上可接受的盐:
式(I)中,
R为C1~C6烷基、C1~C6烯基、C1~C6炔基、氨基或乙酰胺基;
本发明特别优选如下表1中所示的化合物。
表1
本发明所述的化合物为一种蛋白水解靶向嵌合分子(PROTACs),其包括可以与EGFR蛋白底物相结合的部分、可以与E3结合的部分以及连接链,利用这种双功能小分子可以将目标蛋白和细胞内的E3拉近,从而使本来不能与E3结合的EGFR靶蛋白泛素化,进而被蛋白酶体识别并降解。
本发明所述式(I)所示的靶向泛素化诱导EGFR蛋白降解的化合物的制备方法为:
将厄洛替尼(II)溶于有机溶剂中,于室温(20~30℃)下加入化合物(III)、五水硫酸铜和维生素C(Vc),加热至40~90℃反应4~10h,之后经后处理,得到产物(I);
所述厄洛替尼(II)、化合物(III)、五水硫酸铜、维生素C的物质的量之比为1:1:0.15~0.2:0.3~0.4;
所述有机溶剂为二甲基亚砜(DMSO),所述有机溶剂的体积用量以厄洛替尼(II)的物质的量计为5~10L/mol;
优选将五水硫酸铜和维生素C溶于水后投料;
所述后处理的方法为:反应结束后,反应液中加入水,乙酸乙酯萃取,合并有机相,饱和食盐水洗涤,无水硫酸钠干燥,减压浓缩,柱层析分离,以二氯甲烷:甲醇体积比为10:1的混合液为洗脱剂,收集含目标化合物的洗脱液,蒸除溶剂并干燥,得到产物(I);
式(III)中,R、Linker的定义与式(I)中相同。
本发明所述式(I)所示的靶向泛素化诱导EGFR蛋白降解的化合物或其药学上可接受的盐或水合物可应用于制备预防或/和治疗癌症的药物。
本发明通过免疫荧光、免疫印迹分析等实验,证实该小分子化合物可以很好的结合EGFR蛋白,并通过泛素蛋白酶体途径降解EGFR蛋白。
本发明式(I)所示化合物可用于与EGFR蛋白酶活性异常表达相关的疾病中的应用,通过体外活性筛选,发现本发明化合物具有抗肿瘤活性,因此本发明还公开了所述化合物在制备预防或/和治疗癌症的药物中的应用。
所述的癌症为乳腺癌、结肠癌、前列腺癌、胰腺癌、甲状腺乳头状癌、卵巢癌、黑色素瘤、白血病或非小细胞肺癌。优选为非小细胞肺癌,这是由于实验表明该化合物抗非小细胞肺癌活性极高。
本发明化合物可作为唯一的抗癌药物使用,或者与一种或多种其它抗肿瘤药物联合使用。联合治疗通过将各个治疗组分同时,顺序或隔开给药来实现。
此外,本发明还涉及药物组合物,该药物组合物含有式(I)所示化合物或其药学上可接受的盐或水合物和药物上可接受的赋形剂。所述药物上可接受的赋形剂是指任何可用于药物领域的稀释剂、辅助剂和/或载体。
本发明化合物可以与其他活性成分组合使用,只要它们不产生其它不利作用,例如过敏反应。
本发明的药物组合物可配置成若干剂型,其中含有药物领域中常用的一些赋形剂。
具体的剂型例如:口服制剂;可注射的制剂;局部制剂。
口服制剂可为片剂、胶囊剂、溶液或混悬液;注射制剂可为注射溶液或混悬剂,或者可注射的干燥粉末,在注射前加入注射用水可立即使用;局部制剂可为软膏或溶液。
药学上可接受的辅料包括:口服制剂用的粘合剂、润滑剂、崩解剂、助溶剂、稀释剂、稳定剂、悬浮剂、色素或矫味剂;注射制剂用的防腐剂、加溶剂或稳定剂;局部制剂用的基质、稀释剂、润滑剂、防腐剂等。
药物制剂可以经口服或胃肠外方式(如静脉内、皮下、腹膜内或局部)给药,如果某些药物在胃部条件下是不稳定的,可将其配制成肠衣片剂。
与现有技术相比,本发明具有以下有益效果:
本发明选用泊马度胺作为PROTACs中与E3连接酶进行结合的部位,厄洛替尼为靶向EGFR小分子化合物,选用合适的连接链将两者相连接构建PROTACs。体外抗肿瘤活性测试及体外EGFR蛋白降解活性表明,本发明化合物表现出了良好的抗肿瘤活性,并表现出优异的EGFR蛋白降解作用,可用于预防或/和治疗多种癌症,在医药领域具有巨大的应用前景。
附图说明
图1PROTACs技术原理示意图。
图2实施例2得到的化合物ALP-1的核磁谱图。
图3实施例3得到的化合物ALP-2的核磁谱图。
图4实施例4得到的化合物ALP-3的核磁谱图。
图5实施例5中ALP-2和ALP-3不同浓度下EGFR蛋白降解情况。
具体实施方式
下面通过具体实施例进一步描述本发明,但本发明的保护范围并不仅限于此。
本发明中涉及的缩写词意义为:Boc为叔丁氧羰基,DMF为二甲基甲酰胺,DIPEA为二异丙基乙胺,TBAB为四丁基溴化铵,EA为乙酸乙酯,Et为乙基,Me为甲基,M即摩尔,PE为石油醚,Ph为苯基,THF为四氢呋喃,TFA为三氟乙酸,TLC为薄层色谱,NSCLC为非小细胞肺癌,WT为野生型。
下面的合成路线描述了本发明通式(I)化合物的制备,所有的原料都是通过这些路线中描述的方法、通过有机化学领域普通技术人员熟知的方法制备的或者可商购。本发明的全部最终化合物都是通过这些路线中描述的方法或通过与其类似的方法制备的,这些方法是有机化学领域普通技术人员熟知的。这些路线中应用的全部可变因数如下文的定义或如权利要求中的定义。
实施例1:E3配体小分子化合物的制备(化合物6)
化合物6a的制备:
将化合物1a(100mmol)(n=1)溶于30mL DCM中,加入Et3N(200mmol),将TsCl(140mmol)溶于70mL DCM中,在冰浴条件下滴入反应液。过夜反应后,TLC检测(PE:EA=1:2)原料反应完全,产物Rf=0.3。将反应液抽滤,用少量DCM洗涤滤饼,滤液用6N盐酸调节pH至中性,加适量水,用DCM萃取水相两次,合并有机相,减压浓缩,柱层析分离后得到化合物2a,产率40.7%。
将所得化合物2a溶于100mL DMF中,常温下加入NaN3(100mmol),油浴温度100℃条件下反应。反应4h后,TLC检测(PE:EA=1:2)碘显,原料反应完全,产物Rf=0.6。加入大量水,用EA萃取水相4次,合并有机相后,用饱和食盐水洗涤有机相2次,减压浓缩,过柱纯化,得到化合物3a,产率92.1%。
将NaH(10.2mmol)置于50mL圆底烧瓶中,置换N2后,冰浴下加入化合物3a(5mmol)的4mL THF溶液,反应半小时。撤去冰浴,室温下加入溴乙酸叔丁酯,室温下反应6h,TLC检测(PE:EA=2:1)反应完全,产物Rf=0.5。加水淬灭反应,EA萃取水相三次,合并有机相,饱和食盐水洗涤,无水硫酸钠干燥,减压浓缩,柱层析分离,得到化合物4a,产率60.1%。
将化合物4a(2.5mmol)溶于甲醇(4.2mL),将氢氧化钠固体(6.2mmol)溶于水(4.2mL)后加入反应液。过夜反应后,TLC检测(PE:EA=1:1)原料反应完全,将3.0mol/L盐酸调pH=3~4,二氯甲烷萃取,减压浓缩。向此浓缩物中滴加草酰氯(7mmol)。反应30min,减压除去草酰氯,加入4mL DMF和泊马度胺(1.1mmol),于90℃油浴下反应20min,TLC检测(PE:EA=1:2),原料反应完全,产物Rf=0.4。加水,EA萃取,合并有机相,饱和食盐水洗涤,无水硫酸钠干燥,减压浓缩,柱层析纯化,得化合物6a,产率62%。
1H NMR(500MHz,DMSO)δ11.18(s,1H),10.36(s,1H),8.73(d,J=8.4Hz,1H),7.98–7.77(m,1H),7.63(d,J=7.3Hz,1H),5.17(dd,J=12.9,5.4Hz,1H),4.21(s,2H),3.77(dd,J=5.8,3.4Hz,2H),3.69(dd,J=5.7,3.5Hz,2H),3.62–3.45(m,6H),3.35(d,J=5.7Hz,2H),2.91(ddd,J=17.1,13.9,5.4Hz,1H),2.69–2.58(m,1H),2.57–2.47(m,1H),2.09(ddd,J=10.4,5.3,3.1Hz,1H).
化合物6b的制备:
依照化合物6a的制备方法将起始化合物2a改用化合物2b(100mmol)(n=2),其余合成步骤及反应条件相同,得化合物6b,产率为66%。
1H NMR(500MHz,DMSO)δ11.18(s,1H),10.37(s,1H),8.73(d,J=8.4Hz,1H),7.95–7.82(m,1H),7.64(d,J=7.2Hz,1H),5.18(dd,J=12.9,5.4Hz,1H),4.21(s,2H),3.77(dd,J=5.7,3.5Hz,2H),3.68(dd,J=5.6,3.6Hz,2H),3.61–3.47(m,14H),3.42–3.37(m,2H),2.91(ddd,J=17.1,14.0,5.4Hz,1H),2.60(dd,J=19.8,11.2Hz,1H),2.55–2.45(m,1H),2.09(ddd,J=10.3,5.2,3.0Hz,1H).
化合物6c的制备:
依照化合物6a的制备方法将起始化合物2a改用化合物2c(100mmol)(n=3),其余合成步骤及反应条件相同,得化合物6c,产率为64%。
1H NMR(500MHz,DMSO)δ11.17(s,1H),10.37(s,1H),8.73(d,J=8.4Hz,1H),7.91–7.83(m,1H),7.64(d,J=7.2Hz,1H),5.17(dd,J=12.9,5.4Hz,1H),4.21(s,2H),3.77(dd,J=5.7,3.5Hz,2H),3.68(dd,J=5.6,3.6Hz,2H),3.59(dd,J=6.5,3.4Hz,2H),3.57–3.47(m,16H),3.40–3.37(m,2H),2.89(s,1H),2.66–2.58(m,1H),2.55(dd,J=13.5,4.4Hz,1H),2.09(d,J=5.4Hz,1H).
实施例2:PROTACs化合物ALP-1的制备
将实施例1制得的化合物6a(0.11mmol),厄洛替尼7(0.11mmol)溶于1mL DMSO中,开启搅拌。将五水硫酸铜(0.02mmol),维生素C(0.04mmol)溶于0.5mL水加入反应体系,50℃反应4h。TLC检测(EA:MeOH=10:1)原料反应完全。加入水,EA萃取,合并有机相,饱和食盐水洗涤,无水硫酸钠干燥,减压浓缩,柱层析分离,得化合物ALP-1,产率70%。
1H NMR(500MHz,DMSO-d6)δ11.19(s,1H),10.29(s,1H),9.61(s,1H),8.67(d,J=8.4Hz,1H),8.52(s,1H),8.47(s,1H),8.30(s,1H),7.95(s,1H),7.88(d,J=8.1Hz,1H),7.84–7.77(m,1H),7.58(d,J=7.2Hz,1H),7.53(d,J=7.7Hz,1H),7.43(t,J=7.9Hz,1H),7.20(s,1H),5.15(dd,J=12.9,5.4Hz,1H),4.58(t,J=5.1Hz,2H),4.30(dt,J=16.6,4.6Hz,4H),4.13(s,2H),3.86(t,J=5.2Hz,2H),3.82–3.73(m,4H),3.69(dd,J=5.8,3.3Hz,2H),3.62(dd,J=5.8,3.3Hz,2H),3.59–3.52(m,4H),3.36(s,6H),2.90(ddd,J=17.3,14.0,5.4Hz,1H),2.55(s,2H),2.12–2.05(m,1H).
实施例3:PROTACs化合物ALP-2的制备
将实施例1制得的化合物6b(0.35mmol),厄洛替尼7(0.35mmol)溶于2mL DMSO中,开启搅拌。将五水硫酸铜(0.06mmol),维生素C(0.14mmol)溶于2mL水加入反应体系,50℃反应5h。TLC检测(EA:MeOH=10:1)原料反应完全,加入水,EA萃取,合并有机相,饱和食盐水洗涤,无水硫酸钠干燥,减压浓缩,柱层析分离,得化合物ALP-2,产率72%。
1H NMR(500MHz,DMSO-d6)δ11.18(s,1H),10.33(s,1H),9.60(s,1H),8.70(d,J=8.4Hz,1H),8.54(s,1H),8.47(s,1H),8.28(s,1H),7.95(s,1H),7.90(d,J=8.0Hz,1H),7.87–7.82(m,1H),7.61(d,J=7.3Hz,1H),7.54(d,J=7.7Hz,1H),7.45(t,J=7.9Hz,1H),7.22(s,1H),5.16(dd,J=12.9,5.4Hz,1H),4.59(t,J=5.1Hz,2H),4.30(dt,J=14.2,4.5Hz,4H),4.17(s,2H),3.88(t,J=5.2Hz,2H),3.81–3.70(m,6H),3.61(dd,J=5.6,3.6Hz,2H),3.56–3.47(m,8H),3.43(t,J=4.2Hz,6H),2.89(ddd,J=18.3,13.9,5.3Hz,2H),2.61(dd,J=15.2,2.4Hz,1H),2.11–1.95(m,2H).
实施例4:PROTACs化合物ALP-3的制备
将实施例1制得的化合物6c(0.25mmol)、厄洛替尼7(0.25mmol)溶于2mL DMSO中,开启搅拌。将五水硫酸铜(0.05mmol),维生素C(0.10mmol)溶于2mL水加入反应体系,50℃反应7h。TLC检测(EA:MeOH=10:1)原料反应完全,加入水,EA萃取,合并有机相,饱和食盐水洗涤,无水硫酸钠干燥,减压浓缩,柱层析分离,得化合物ALP-3,产率76%。
1H NMR(500MHz,DMSO-d6)δ10.34(s,1H),9.77(s,1H),8.73–8.68(m,1H),8.54(s,1H),8.47(s,1H),8.31(s,1H),8.02(s,1H),7.91(d,J=9.1Hz,1H),7.88–7.82(m,1H),7.62(d,J=7.2Hz,1H),7.54(d,J=7.7Hz,1H),7.44(t,J=7.9Hz,1H),7.21(s,1H),5.19–5.14(m,2H),4.76(dt,J=6.6,3.3Hz,2H),4.59(t,J=5.1Hz,2H),4.34–4.31(m,2H),4.30–4.27(m,2H),4.18(s,2H),3.80–3.72(m,12H),3.65–3.62(m,4H),3.56–3.54(m,2H),3.52–3.47(m,6H),3.41(s,6H),2.91–2.85(m,1H),2.64–2.61(m,2H),2.08(ddd,J=10.3,5.2,3.0Hz,1H).
实施例5:活性测定
(1)MTT法测定PROTACs化合物对肿瘤细胞增殖抑制活性
本次活性筛选研究主要涉及以下几种非小细胞肺癌细胞株,其名称及特点如下表2所示:
表2非小细胞肺癌(NSCLC)细胞系种类及突变位点
将处于对数生长期的肿瘤细胞(H1975、PC9、PC9-IR、HCC827)分别以5×103、5×103、5×103、1.5×103个细胞接种于96孔板,培育24h,加入不同浓度PROTACs化合物后,细胞在37℃、5%CO2条件下继续培养72小时,每孔加入20uL MTT(5mg/mL)溶液继续培养4小时,用DMSO溶解结晶,用酶联免疫检测仪在490nm波长处测定其OD值并计算IC50,具体结果如下表3所示,化合物ALP-2和ALP-3均具有较好的抑瘤活性,尤其是对PC9细胞株,其IC50值分别为4.69μmol·L-1和4.36μmol·L-1.。
表3化合物ALP-1~ALP-3对不同NSCLC细胞系的生长抑制作用
(2)Western Blot测定EGFR蛋白降解作用
ALP-2和ALP-3化合物处理PC9细胞48h后,用预冷的PBS洗涤2次,加入适量含1×PMSF和1×cOmplete的RIPA裂解液收集细胞,冰上裂解细胞30min后,4℃,12000r/min,30min离心,取上清,即细胞总蛋白。用BCA法定量检测蛋白量,用5×蛋白上样缓冲液稀释蛋白后100℃变性5min。蛋白在SDS—PAGE电泳分离,转膜,封闭2h,一抗4℃孵育过夜。TBST洗膜,二抗1:2000孵育2h,洗膜,化学发光后显影。
实验结果表明(图5),ALP-2和ALP-3均能降解EGFR蛋白,其中化合物ALP-3具有较佳的降解效果。
Claims (8)
4.如权利要求3所述的制备方法,其特征在于,所述厄洛替尼(II)、化合物(III)、五水硫酸铜、维生素C的物质的量之比为1:1:0.15~0.2:0.3~0.4。
5.如权利要求3所述的制备方法,其特征在于,所述有机溶剂为二甲基亚砜,所述有机溶剂的体积用量以厄洛替尼(II)的物质的量计为5~10L/mol。
6.如权利要求3所述的制备方法,其特征在于,所述后处理的方法为:反应结束后,反应液中加入水,乙酸乙酯萃取,合并有机相,饱和食盐水洗涤,无水硫酸钠干燥,减压浓缩,柱层析分离,以二氯甲烷:甲醇体积比为10:1的混合液为洗脱剂,收集含目标化合物的洗脱液,蒸除溶剂并干燥,得到产物(I)。
7.如权利要求1所述式(I)所示的靶向泛素化诱导EGFR蛋白降解的化合物或其药学上可接受的盐或水合物在制备预防或/和治疗癌症的药物中的应用。
8.一种药物组合物,其特征在于,所述药物组合物含有式(I)所示化合物或其药学上可接受的盐或水合物和药物上可接受的赋形剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110468180.6A CN113603676B (zh) | 2021-04-28 | 2021-04-28 | 基于厄洛替尼靶向降解egfr蛋白小分子化合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110468180.6A CN113603676B (zh) | 2021-04-28 | 2021-04-28 | 基于厄洛替尼靶向降解egfr蛋白小分子化合物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113603676A CN113603676A (zh) | 2021-11-05 |
CN113603676B true CN113603676B (zh) | 2022-05-24 |
Family
ID=78303378
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110468180.6A Active CN113603676B (zh) | 2021-04-28 | 2021-04-28 | 基于厄洛替尼靶向降解egfr蛋白小分子化合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113603676B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114085215B (zh) * | 2021-11-15 | 2023-07-25 | 南方医科大学 | 一种富马酸酰胺类化合物或其药学上可接受的盐及其制备方法和应用 |
CN114853751B (zh) * | 2022-05-13 | 2024-01-16 | 郑州大学第一附属医院 | 一组吩噻嗪类衍生物及其应用 |
CN115403561B (zh) * | 2022-08-22 | 2024-03-08 | 西安交通大学 | 一种基于沙利度胺类似物的细胞内自组装蛋白降解剂及其制备方法和应用 |
CN115385859B (zh) * | 2022-08-22 | 2024-03-08 | 西安交通大学 | 一种可细胞内自组装的蛋白降解剂及其制备方法和应用 |
CN115572283A (zh) * | 2022-10-24 | 2023-01-06 | 河南湾流生物科技有限公司 | 一种泊马度胺类饲料添加剂及其制备方法和应用 |
CN115636815B (zh) * | 2022-10-24 | 2023-10-27 | 新乡学院 | 一种泊马度胺连接脲类化合物的制备方法和应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104736569A (zh) * | 2012-01-12 | 2015-06-24 | 耶鲁大学 | 通过e3泛素连接酶增强靶蛋白质及其他多肽降解的化合物和方法 |
CN110372669A (zh) * | 2019-06-19 | 2019-10-25 | 浙江省医学科学院 | 一种基于crbn配体诱导egfr降解的化合物及其制备方法、药物组合物和应用 |
CN110372693A (zh) * | 2018-07-04 | 2019-10-25 | 清华大学 | 一种靶向降解bet蛋白的化合物及其应用 |
CN112176418A (zh) * | 2019-07-05 | 2021-01-05 | 中国科学院上海有机化学研究所 | 高通量的化合物库构建和筛选方法以及反应装置 |
CN112174940A (zh) * | 2019-07-05 | 2021-01-05 | 上海中医药大学 | 3-(6,7-双(2-甲氧乙氧基)-喹唑啉-4-胺基)苯基-1h-三氮唑衍生物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112019015484A2 (pt) * | 2017-01-31 | 2020-04-28 | Arvinas Operations Inc | ligantes de cereblon e compostos bifuncionais compreendendo os mesmos |
-
2021
- 2021-04-28 CN CN202110468180.6A patent/CN113603676B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104736569A (zh) * | 2012-01-12 | 2015-06-24 | 耶鲁大学 | 通过e3泛素连接酶增强靶蛋白质及其他多肽降解的化合物和方法 |
CN110372693A (zh) * | 2018-07-04 | 2019-10-25 | 清华大学 | 一种靶向降解bet蛋白的化合物及其应用 |
CN110372669A (zh) * | 2019-06-19 | 2019-10-25 | 浙江省医学科学院 | 一种基于crbn配体诱导egfr降解的化合物及其制备方法、药物组合物和应用 |
CN112176418A (zh) * | 2019-07-05 | 2021-01-05 | 中国科学院上海有机化学研究所 | 高通量的化合物库构建和筛选方法以及反应装置 |
CN112174940A (zh) * | 2019-07-05 | 2021-01-05 | 上海中医药大学 | 3-(6,7-双(2-甲氧乙氧基)-喹唑啉-4-胺基)苯基-1h-三氮唑衍生物 |
Also Published As
Publication number | Publication date |
---|---|
CN113603676A (zh) | 2021-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113603676B (zh) | 基于厄洛替尼靶向降解egfr蛋白小分子化合物及其制备方法和应用 | |
CN109928956B (zh) | 一种靶向泛素化降解egfr蛋白的化合物及其药物组合物和应用 | |
CN110372669B (zh) | 一种基于crbn配体诱导egfr降解的化合物及其制备方法、药物组合物和应用 | |
CN109983016B (zh) | 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途 | |
CN111377871B (zh) | 一种fak抑制剂及其联合用药物 | |
CN111574498A (zh) | 基于来那度胺靶向降解egfr蛋白小分子化合物及其制备与应用 | |
CN110204532B (zh) | 一种靶向egfr蛋白降解的化合物及其制备方法和应用 | |
CN115353508B (zh) | 5-吡啶-1h-吲唑类化合物、药物组合物和应用 | |
WO2016124160A1 (zh) | 作为egfr抑制剂的嘧啶并嘧啶二酮衍生物及其应用 | |
CN110563703A (zh) | 基于crbn配体诱导parp-1降解的化合物及制备方法和应用 | |
WO2022199547A1 (zh) | 一种7,9-二氢嘌呤衍生物及其制药用途 | |
De Moura et al. | Palladium (ii) complexes bearing 1-iminothiolate-3, 5-dimethylpyrazoles: synthesis, cytotoxicity, DNA binding and enzymatic inhibition studies | |
CN113444069B (zh) | 一类2-芳基-4-(1h-吡唑-3-基)吡啶类lsd1/hdac双靶点抑制剂 | |
CN102827116B (zh) | 含α-芳基-γ-亚甲基丁烯内酯类化合物及其合成方法和用途 | |
CN111471048B (zh) | 一种具有含氮桥环、螺环或并环结构的化合物及其用途 | |
CN106892922B (zh) | 作为egfr抑制剂的5,8-二氢蝶啶-6,7-二酮衍生物及其应用 | |
CN107266466A (zh) | 灯盏乙素生物素标记探针的应用及相关pkm2激酶抑制剂 | |
CN114044775B (zh) | 一种靶向泛素化诱导bcr-abl蛋白降解的化合物及其应用 | |
Wang et al. | Design, synthesis and biological evaluation of some novel thiazole-2-carboxamide derivatives as antitumor agents | |
CN111233809B (zh) | 一种Millepachine-CA-4衍生物及其制备方法和应用 | |
CN113527195B (zh) | 一类5-芳基烟酰胺类lsd1/hdac双靶点抑制剂、其制备方法及应用 | |
CN115477639A (zh) | 一种以fgfr1为靶点的多取代嘧啶类化合物及其制备方法和用途 | |
CN114702544B (zh) | 一种氨基甾体化合物及其制备方法和应用 | |
CN114539110B (zh) | 含有ras/raf蛋白干扰基团的hdac抑制剂及其制备方法 | |
CN115043784B (zh) | 一种联苯-1,2,3-三氮唑偶联物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |